UT Southwestern’s Dr. Lu Le, left, and graduate student Amish Patel published a study that found by inhibiting a key protein, a rare, incurable type of soft-tissue cancer could be eradicated. Credit: UT Southwestern Medical Center
A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth, UT Southwestern Medical Center researchers report.
In the study, published online today in Cell Reports, scientists found that inhibiting the action of a protein called BRD4 caused cancer cells to die in a mouse model of malignant peripheral nerve sheath tumors (MPNSTs).
"This study identifies a potential new therapeutic target to combat MPNST, an incurable type of cancer that is typically fatal," said Dr. Lu Le, Assistant Professor of Dermatology at UT Southwestern and senior author of the study. "The findings also provide important insight into what causes these tumors to develop."
MPNSTs are highly aggressive sarcomas that form around nerves. These tumors can develop sporadically, but about half of cases are in patients with a genetic disorder called neurofibromatosis type 1 (NF1) that affects 1 in 3,500 people. About 10 percent of NF1 patients will develop MPNST, which usually evolves from a benign but often large and disfiguring tumor called a plexiform neurofibroma.
Up to now, the preferred treatment for MPNST has been surgical removal, but that oftentimes is difficult or impossible due to the tumor's location around nerves. Radiation and chemotherapy are other options, but their effectiveness is limited. The five-year survival rate for MPNST patients is about 50 percent.
By studying changes in cells as they evolved into cancerous MPNSTs, researchers in Dr. Le's laboratory were able to determine that BRD4, a bromodomain protein that binds to DNA to regulate gene activation, is expressed at an unusually high level in MPNST cancer cells. This action caused another protein called BCL-2 to keep cancer cells from dying. Alternately, when researchers inhibited BRD4 either genetically in the mice or pharmacologically by administering a compound called JQ1, a promoter of cell death, the tumors shrank.
"These treatments suppressed tumor growth and caused the cancer cells to undergo apoptosis, or cell death. This is why BRD4 inhibition is exquisitely effective against MPNSTs and may represent a paradigm shift in therapy for these patients," Dr. Le said.
The same class of drug used in the experiments is currently being evaluated in phase 1 and 2 trials for treatment of leukemia and a subtype of lung cancer. Meanwhile, UT Southwestern is working with a pharmaceutical company to develop a similar BRD4-inhibiting drug to launch a clinical trial for MPNST patients.
New drugs are desperately needed to treat MPNST and provide hope to NF1 patients at highest risk for this cancer, said Dr. Le, who also serves as Co-director of UT Southwestern's Comprehensive Neurofibromatosis Clinic. The clinic offers neurofibromatosis patients access to the latest clinical trials and treatments. Co-directed by Dr. Laura Klesse, Assistant Professor of Pediatrics, the clinic is part of the Harold C. Simmons Comprehensive Cancer Center and serves patients with all three types of hereditary neurofibromatosis, including the dominant NF1 type and rarer NF2 and Schwannomatosis forms.
Explore further: Scientists make mouse model of human cancer, demonstrate cure
Medical Xpress on facebook
Related Stories
Scientists make mouse model of human cancer, demonstrate cure
Mar 05, 2013
UT Southwestern Medical Center scientists report the first successful blocking of tumor development in a genetic mouse model of an incurable human cancer.
Researchers develop model for better testing, targeting of malignant peripheral nerve sheath tumors
May 20, 2013
University of Minnesota Medical School researchers from the Masonic Cancer Center, University of Minnesota, in partnership with the University's Brain Tumor Program, have developed a new mouse model of malignant peripheral ...
Neurofibroma mouse model predicts response to therapy in humans
Nov 05, 2013
A mouse model predicted that inhibition of the enzyme MEK using targeted therapy may provide an effective, single-agent treatment for pediatric patients with neurofibroma, and early results from a phase I trial support this ...
Research identifies targeted molecular therapy for untreatable NF1 tumors
Dec 10, 2012
Researchers conducting a preclinical study in mice successfully used targeted molecular therapy to block mostly untreatable nerve tumors that develop in people with the genetic disorder Neurofibromatosis 1 (NF1).
Researchers identify a switch that controls growth of most aggressive brain tumor cells
Sep 20, 2013
Researchers at UT Southwestern Medical Center have identified a cellular switch that potentially can be turned off and on to slow down, and eventually inhibit the growth of the most commonly diagnosed and ...
Recommended for you
Rock And Rho: Proteins that help cancer cells groove
4 minutes ago
Biologists at The Johns Hopkins University have discovered that low oxygen conditions, which often persist inside tumors, are sufficient to initiate a molecular chain of events that transforms breast cancer ...
Systematic, genomic study of cervical cancer points to potential therapeutics, sheds light on HPV role
22 hours ago
Researchers from the Boston area, Mexico, and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations. The study identified recurrent genetic mutations not previously found in ...
Radiotherapy is less often used by breast cancer patients with young children
Dec 24, 2013
Radiotherapy (RT) after breast conserving surgery (BCS) has been shown to reduce the risk of breast cancer (BC) recurrence. However, although younger women tend to have more aggressive tumors and have higher risks of recurrence ...
USPSTF supports counseling, BRCA tests for at-risk women
Dec 24, 2013
(HealthDay)—Nine of 10 women do not need and should not receive genetic testing to see if they are at risk for breast or ovarian cancer, an influential panel of health experts announced Monday.
Gene therapy method targets tumor blood vessels
Dec 23, 2013
Working in mice, researchers at Washington University School of Medicine in St. Louis report developing a gene delivery method long sought in the field of gene therapy: a deactivated virus carrying a gene ...
Study defines roles and responsibilities of patient navigators
Dec 23, 2013
New research out of the George Washington University Cancer Institute (GWCI) defines the roles and responsibilities of patient navigators. With the rapid growth of patient navigation, the paper seeks to develop a framework ...
User comments
© Medical Xpress 2011-2013, Science X network
UT Southwestern’s Dr. Lu Le, left, and graduate student Amish Patel published a study that found by inhibiting a key protein, a rare, incurable type of soft-tissue cancer could be eradicated. Credit: UT Southwestern Medical Center
A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth, UT Southwestern Medical Center researchers report.
In the study, published online today in Cell Reports, scientists found that inhibiting the action of a protein called BRD4 caused cancer cells to die in a mouse model of malignant peripheral nerve sheath tumors (MPNSTs).
"This study identifies a potential new therapeutic target to combat MPNST, an incurable type of cancer that is typically fatal," said Dr. Lu Le, Assistant Professor of Dermatology at UT Southwestern and senior author of the study. "The findings also provide important insight into what causes these tumors to develop."
MPNSTs are highly aggressive sarcomas that form around nerves. These tumors can develop sporadically, but about half of cases are in patients with a genetic disorder called neurofibromatosis type 1 (NF1) that affects 1 in 3,500 people. About 10 percent of NF1 patients will develop MPNST, which usually evolves from a benign but often large and disfiguring tumor called a plexiform neurofibroma.
Up to now, the preferred treatment for MPNST has been surgical removal, but that oftentimes is difficult or impossible due to the tumor's location around nerves. Radiation and chemotherapy are other options, but their effectiveness is limited. The five-year survival rate for MPNST patients is about 50 percent.
By studying changes in cells as they evolved into cancerous MPNSTs, researchers in Dr. Le's laboratory were able to determine that BRD4, a bromodomain protein that binds to DNA to regulate gene activation, is expressed at an unusually high level in MPNST cancer cells. This action caused another protein called BCL-2 to keep cancer cells from dying. Alternately, when researchers inhibited BRD4 either genetically in the mice or pharmacologically by administering a compound called JQ1, a promoter of cell death, the tumors shrank.
"These treatments suppressed tumor growth and caused the cancer cells to undergo apoptosis, or cell death. This is why BRD4 inhibition is exquisitely effective against MPNSTs and may represent a paradigm shift in therapy for these patients," Dr. Le said.
The same class of drug used in the experiments is currently being evaluated in phase 1 and 2 trials for treatment of leukemia and a subtype of lung cancer. Meanwhile, UT Southwestern is working with a pharmaceutical company to develop a similar BRD4-inhibiting drug to launch a clinical trial for MPNST patients.
New drugs are desperately needed to treat MPNST and provide hope to NF1 patients at highest risk for this cancer, said Dr. Le, who also serves as Co-director of UT Southwestern's Comprehensive Neurofibromatosis Clinic. The clinic offers neurofibromatosis patients access to the latest clinical trials and treatments. Co-directed by Dr. Laura Klesse, Assistant Professor of Pediatrics, the clinic is part of the Harold C. Simmons Comprehensive Cancer Center and serves patients with all three types of hereditary neurofibromatosis, including the dominant NF1 type and rarer NF2 and Schwannomatosis forms.
Explore further: Scientists make mouse model of human cancer, demonstrate cure
Medical Xpress on facebook
Related Stories
Scientists make mouse model of human cancer, demonstrate cure
Mar 05, 2013
UT Southwestern Medical Center scientists report the first successful blocking of tumor development in a genetic mouse model of an incurable human cancer.
Researchers develop model for better testing, targeting of malignant peripheral nerve sheath tumors
May 20, 2013
University of Minnesota Medical School researchers from the Masonic Cancer Center, University of Minnesota, in partnership with the University's Brain Tumor Program, have developed a new mouse model of malignant peripheral ...
Neurofibroma mouse model predicts response to therapy in humans
Nov 05, 2013
A mouse model predicted that inhibition of the enzyme MEK using targeted therapy may provide an effective, single-agent treatment for pediatric patients with neurofibroma, and early results from a phase I trial support this ...
Research identifies targeted molecular therapy for untreatable NF1 tumors
Dec 10, 2012
Researchers conducting a preclinical study in mice successfully used targeted molecular therapy to block mostly untreatable nerve tumors that develop in people with the genetic disorder Neurofibromatosis 1 (NF1).
Researchers identify a switch that controls growth of most aggressive brain tumor cells
Sep 20, 2013
Researchers at UT Southwestern Medical Center have identified a cellular switch that potentially can be turned off and on to slow down, and eventually inhibit the growth of the most commonly diagnosed and ...
Recommended for you
Rock And Rho: Proteins that help cancer cells groove
4 minutes ago
Biologists at The Johns Hopkins University have discovered that low oxygen conditions, which often persist inside tumors, are sufficient to initiate a molecular chain of events that transforms breast cancer ...
Systematic, genomic study of cervical cancer points to potential therapeutics, sheds light on HPV role
22 hours ago
Researchers from the Boston area, Mexico, and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations. The study identified recurrent genetic mutations not previously found in ...
Radiotherapy is less often used by breast cancer patients with young children
Dec 24, 2013
Radiotherapy (RT) after breast conserving surgery (BCS) has been shown to reduce the risk of breast cancer (BC) recurrence. However, although younger women tend to have more aggressive tumors and have higher risks of recurrence ...
USPSTF supports counseling, BRCA tests for at-risk women
Dec 24, 2013
(HealthDay)—Nine of 10 women do not need and should not receive genetic testing to see if they are at risk for breast or ovarian cancer, an influential panel of health experts announced Monday.
Gene therapy method targets tumor blood vessels
Dec 23, 2013
Working in mice, researchers at Washington University School of Medicine in St. Louis report developing a gene delivery method long sought in the field of gene therapy: a deactivated virus carrying a gene ...
Study defines roles and responsibilities of patient navigators
Dec 23, 2013
New research out of the George Washington University Cancer Institute (GWCI) defines the roles and responsibilities of patient navigators. With the rapid growth of patient navigation, the paper seeks to develop a framework ...
User comments
© Medical Xpress 2011-2013, Science X network
0 comments:
Post a Comment